Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
With targeted therapy, the reason for treatment is finding a specific molecular change in the tumor. The side effects, or ‘symptoms,’ are often unique and can affect the skin or metabolism because the drugs block pathways that are also important in healthy tissues. Unlike chemotherapy, which harms all fast-growing cells, the side effects of targeted therapy depend on the normal role of the targeted protein. This section looks at when targeted therapy is used and the reasons behind its specific side effects.
Targeted therapy is only given when a specific biological change is found, such as a mutation, extra copies of a gene, or too much of a certain protein. For example, an EGFR mutation in lung cancer means an EGFR inhibitor can be used, and too much HER2 in breast cancer means anti-HER2 therapy is needed. If these changes are not present, the drugs will not work. This approach shifts cancer treatment from focusing on the organ to focusing on the genetic changes in the tumor.
The most common side effect of EGFR inhibitors is a rash that looks like acne. This is not an allergy but happens because the drug blocks EGFR, which is important for skin and hair cell growth. When this pathway is blocked, skin cells stop growing normally, causing inflammation and sometimes infection. Interestingly, a more severe rash often means the drug is working well against the tumor. Treating this rash requires special creams and antibiotics, not regular acne treatments.
Targeting the tumor vasculature via VEGF (Vascular Endothelial Growth Factor) inhibition can lead to distinct vascular side effects. VEGF is essential for maintaining the endothelial lining of blood vessels and for regulating blood pressure through nitric oxide production. Blocking this pathway causes vasoconstriction and rarefaction (loss) of microvessels, leading to systemic hypertension. This “symptom” must be rigorously managed to prevent cardiovascular complications. Furthermore, because VEGF is critical for wound healing, inhibitors can lead to wound dehiscence or bleeding complications, necessitating the suspension of therapy around the time of any surgical intervention.
Cardiotoxicity is a specific concern with HER2-targeted agents. HER2 signaling is involved in the physiological stress response of cardiac myocytes. Blocking this pathway can lead to a decrease in left ventricular ejection fraction and, in rare cases, overt heart failure. Unlike anthracycline-induced damage, this toxicity is often reversible upon cessation of the drug, representing a form of cellular stunning rather than permanent destruction.
Many targeted agents, particularly those affecting the PI3K/AKT/mTOR pathway, interfere with glucose metabolism. These pathways are central to insulin signaling. Their inhibition can induce hyperglycemia and hyperlipidemia, mimicking a state of metabolic syndrome or Type 2 diabetes. This requires careful monitoring of blood glucose and lipids, and often the initiation of oral hypoglycemics. Additionally, multikinase inhibitors that target the thyroid hormone receptors or blood supply to the thyroid gland can cause hypothyroidism, manifesting as fatigue and weight gain, which can be mistakenly attributed to the cancer itself.
Molecular Signaling of Toxicity
Taking targeted therapy for a long time can make it harder for the body to repair itself. Blocking pathways like EGFR and VEGF over time can cause thinning of the lining of the mouth, hair loss, and slow wound healing. These changes are often subtle but can affect tissue strength. Ongoing care includes special wound care and steps to protect heart health while on these drugs.
Send us all your questions or requests, and our expert team will assist you.
EGFR inhibitors block the Epidermal Growth Factor Receptor protein, which drives cancer growth. However, this protein is also essential for the normal growth and health of skin cells and hair follicles. When the drug blocks EGFR in the skin, it causes inflammation and disrupts the protective barrier, leading to an acne-like rash, dry skin, and nail changes.
Drugs that target angiogenesis (blood vessel growth), such as VEGF inhibitors, affect the lining of normal blood vessels. They reduce nitric oxide production, a molecule that helps blood vessels relax. This causes the vessels to constrict and stiffen, increasing the pressure required to pump blood through them and leading to hypertension.
Hand Foot Syndrome, or palmar plantar erythrodysesthesia, is a side effect where the skin on the palms of the hands and soles of the feet becomes red, tender, and may peel or blister. In targeted therapy (specifically, multikinase inhibitors), it typically presents as painful calluses at pressure points. It is caused by the drug affecting blood vessels and the mechanisms involved in skin repair in these high-friction areas.
Yes, specific targeted therapies, particularly MEK and BRAF inhibitors, can affect the eyes. They may cause fluid to build up under the retina or cause inflammation, leading to blurred vision, light sensitivity, or spots in the vision. Regular eye exams are often required during treatment to detect these changes early.
Some targeted therapies, particularly those that inhibit the c-KIT or PDGFR pathways, can interfere with melanin production, the pigment that gives hair its color. This can lead to depigmentation, where the hair turns white or grey during treatment. Interestingly, in some cases, hair can repigment or even curl differently once treatment is stopped or adjusted.
Many people can live with stage 4 cancer for months without obvious signs. Advanced cancers often cause vague symptoms. These symptoms are often mistaken for
Breast cancer diagnosis has changed a lot with new genetic tests. Now, we can give treatments that fit each patient’s genes. The signature test for
Breast cancer diagnosis and treatment rely on specific tumor markers. At Liv Hospital, we focus on three key markers: estrogen receptor (ER), progesterone receptor (PR),
Explore ivermectin cancer clinical trials. Get amazing news on scary treatments and find powerful, vital hope for new rectal therapies. We are seeing a big
When chemotherapy stops working for multiple myeloma, patients face a tough challenge. The disease starts to grow again because it has become resistant. This can
Neuroendocrine tumors (NETs) have long been tough to treat. But, new hope has arrived with the FDA’s approval of cabozantinib, a targeted therapy. This is
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
